KAON CL
Clinical safety rating
cautionComprehensive clinical and safety monograph for KAON CL (KAON CL).
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
| Metabolism | Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination. |
| Excretion | Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease). |
| Protein binding | Minimal protein binding (<1%); not significantly bound to plasma proteins. |
| Volume of Distribution | Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration. |
| Bioavailability | Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high. |
| Onset of Action | Oral solution: onset within 30 minutes; extended-release tablets: slower onset, typically 1–2 hours. |
| Duration of Action | Effect lasts 2–4 hours for immediate-release formulations; extended-release products maintain effect for 8–12 hours with careful dosing to avoid hyperkalemia. |
| Molecular Weight | 74.55 |
Oral: 20 mEq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 mEq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 mL/min: contraindicated due to risk of hyperkalemia. |
| Liver impairment | No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances. |
| Pediatric use | Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 mEq/kg/day in divided doses, not to exceed 1 mEq/kg per single dose or maximum 4 mEq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed. |
| Geriatric use | Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 mEq twice daily) with close monitoring of serum potassium and renal function. Avoid if eGFR < 30 mL/min/1.73 m². |
| 1st trimester | Potassium chloride is generally considered safe in recommended doses. However, high doses may be associated with adverse effects. Use only if clearly needed. |
| 2nd trimester | Same as T1. No evidence of teratogenicity with standard dosing. Monitor serum potassium levels. |
| 3rd trimester | Use with caution due to risk of hyperkalemia in the mother and neonate. Avoid high doses. |
Clinical note
Comprehensive clinical and safety monograph for KAON CL (KAON CL).
| Placental transfer | Potassium crosses the placenta by active transport. Fetal serum potassium is slightly higher than maternal. Limited data on exogenous potassium. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Supplementation is unlikely to affect the infant if maternal serum potassium is within normal limits. However, high maternal doses may lead to hyperkalemia in the infant. |
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester. |
| Fetal Monitoring | Monitor serum potassium levels periodically during pregnancy; fetal monitoring only if maternal electrolyte imbalance occurs. |
| Fertility Effects | No known adverse effects on fertility. |
■ FDA Black Box Warning
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydrationHeat cramps
| Precautions | Hyperkalemia risk, especially in renal impairment, Avoid solid oral forms in patients with esophageal stricture or delayed GI transit, May exacerbate metabolic alkalosis, Monitor serum potassium levels regularly |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation. |
| Clinical Pearls | KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails. |
| Patient Advice | Take this medication with a full glass of water and with food to reduce stomach upset. · Do not crush, chew, or break extended-release tablets; swallow them whole. · Avoid salt substitutes containing potassium unless approved by your doctor. · Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion. · Keep all appointments for blood tests to monitor kidney function and potassium levels. |
Loading safety data…